Intellia Therapeutics (NTLA) Stock Forecast, Price & News

18 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Intellia Therapeutics in the last twelve months. There are currently 3 hold ratings and 15 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "moderate buy" NTLA shares.
View NTLA analyst ratings or view top-rated stocks.

18 Wall Street analysts have issued 1-year target prices for Intellia Therapeutics' stock. Their NTLA share price forecasts range from $40.00 to $120.00. On average, they anticipate the company's stock price to reach $80.18 in the next year. This suggests a possible upside of 153.6% from the stock's current price.
View analysts price targets for NTLA or view top-rated stocks among Wall Street analysts.

Intellia Therapeutics' stock was trading at $34.89 on January 1st, 2023. Since then, NTLA shares have decreased by 9.4% and is now trading at $31.62.
View the best growth stocks for 2023 here.

The company is scheduled to release its next quarterly earnings announcement on Thursday, November 2nd 2023.
View our NTLA earnings forecast.

Intellia Therapeutics, Inc. (NASDAQ:NTLA) issued its quarterly earnings data on Thursday, August, 3rd. The company reported ($1.40) EPS for the quarter, missing the consensus estimate of ($1.32) by $0.08. The company earned $13.59 million during the quarter, compared to the consensus estimate of $12.08 million. Intellia Therapeutics had a negative trailing twelve-month return on equity of 41.64% and a negative net margin of 854.92%. Intellia Therapeutics's revenue was down 3.1% on a year-over-year basis. During the same quarter in the prior year, the business earned ($1.33) earnings per share.

ETFs with the largest weight of Intellia Therapeutics (NASDAQ:NTLA) stock in their portfolio include Kelly CRISPR & Gene Editing Technology ETF (XDNA), Morningstar US Small Growth (MSGR), ARK Genomic Revolution ETF (ARKG), Horizon Kinetics Medical ETF (MEDX), ARK Innovation ETF (ARKK), Global X Genomics & Biotechnology ETF (GNOM), iShares Genomics Immunology and Healthcare ETF (IDNA) and Franklin Genomic Advancements ETF (HELX).

12 employees have rated Intellia Therapeutics Chief Executive Officer John Leonard, M.D. on Glassdoor.com. John Leonard, M.D. has an approval rating of 73% among the company's employees.

Based on aggregate information from My MarketBeat watchlists, some companies that other Intellia Therapeutics investors own include Editas Medicine (EDIT), CRISPR Therapeutics (CRSP), NVIDIA (NVDA), Alibaba Group (BABA), Block (SQ), Micron Technology (MU), Advanced Micro Devices (AMD), Intel (INTC), Invitae (NVTA) and Cisco Systems (CSCO).

(NTLA) raised $85 million in an IPO on Friday, May 6th 2016. The company issued 5,000,000 shares at $16.00-$18.00 per share. Credit Suisse, Jefferies and Leerink Partners served as the underwriters for the IPO and Wedbush PacGrow was co-manager.

Intellia Therapeutics trades on the NASDAQ under the ticker symbol "NTLA."

Shares of NTLA stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

One share of NTLA stock can currently be purchased for approximately $31.62.

Intellia Therapeutics (NASDAQ:NTLA) has a market capitalization of $2.80 billion and generates $52.12 million in revenue each year. The company earns $-474,190,000.00 in net income (profit) each year or ($5.46) on an earnings per share basis.

The company employs 598 workers across the globe.

Intellia Therapeutics' mailing address is 40 Erie Street Suite 130, Cambridge MA, 02139. The official website for the company is www.intelliatx.com. The company can be reached via phone at (857) 285-6200 or via email at lina.li@intelliatx.com.